Cardiogen Reconstitution Calculator

No. No regulatory approval or human clinical trial data for Cardiogen were identified in the reviewed corpus. Evidence is limited to animal and tissue-culture studies. Human use remains investigational.

Cardiogen is a synthetic short peptide bioregulator from the Khavinson peptide-medicine program. Ultrashort peptides of 2–7 amino acids can enter the cell nucleus, interact with DNA and histones, and regulate gene expression and protein synthesis. Di- and tripeptides may use PEPT1/2 and LAT1/2 transporters for tissue uptake.

Direct human repair data are absent. In organotypic myocardium tissue culture from young and old rats, Cardiogen showed tissue-specific effects on myocardial tissue development. In an adrenaline-induced stress model in rats, Cardiogen injection normalized heart rate, reduced arrhythmia manifestations, and compensated stress-related changes in relative heart, adrenal, and spleen mass.

No human dose is established. Preclinical studies used injection in rats, but exact doses are not standardized in the available abstracts. In community use, peptide bioregulator courses are often given as short 10–20 day intramuscular/subcutaneous cycles at microgram to low-milligram doses (community protocol). This is not validated human dosing.

No safety data support use during pregnancy or lactation. Short peptides can regulate gene expression and cell differentiation. Avoid use in pregnancy, lactation, and in children unless under a formal research protocol.

Preclinical exposure was short-term. No human duration data exist. Community protocols typically use 10–20 day courses, repeated 2–3 times per year (community protocol). Continuous long-term use is unsupported.

Within the Khavinson peptide class, Cardiogen is one of several tissue-targeted short peptides, alongside Thymalin, Epithalamin, Cortexin, and others. Its myocardium-specific activity in tissue culture distinguishes it, but no comparative human data exist for any peptide bioregulator in this class.

Lyophilized injectable peptide vials are generally stored refrigerated at 2–8°C, and after reconstitution should be kept refrigerated and used within 7–14 days (community protocol). For travel, use a cold pack or insulin cooler and carry documentation. Specific stability data for Cardiogen are not available in the reviewed corpus.